Saudi Arabia inaugurates first local insulin manufacturing facility, advancing healthcare self-sufficiency
In a landmark moment for Saudi Arabia's healthcare sector, the Kingdom inaugurated its first local insulin manufacturing facility, a key milestone in advancing pharmaceutical self-sufficiency under Vision 2030.
The state-of-the-art facility, established through a collaboration between Sanofi, Sudair Pharma Company (SPC), and NUPCO, aims to enhance national drug security and improve access to life-saving insulin for millions of patients living with diabetes.
The inauguration ceremony was attended by Bandar Al-Khorayef, Minister of Industry and Mineral Resources, alongside senior government officials, healthcare leaders, and industry partners.
With diabetes affecting nearly 19% of Saudi Arabia's adult population, ensuring a stable and reliable supply of insulin has been a national priority. Historically reliant on imports, the Kingdom is now taking a transformative step toward localizing production to reduce supply chain vulnerabilities and provide more accessible treatment options.
Preeti Futnani, MCO Lead and Specialty Care General Manager for Greater Gulf at Sanofi, underscored the company's long-standing commitment to Saudi Arabia and its role in supporting the nation's health transformation.
'Sanofi's journey in Saudi Arabia has always been about building something meaningful, and today, we take a major step forward,' Futnani stated.
'With this insulin manufacturing facility, we are not just producing medicine—we are investing in the country's future by ensuring a reliable supply of high-quality insulin, reducing dependency on imports, and empowering local talent to sustain this progress.'
Once fully operational, the facility is expected to produce approximately 15 million insulin pens annually, covering the needs of 500,000 patients across Saudi Arabia. This production milestone will provide 70% of the insulin required by diabetic patients in the Kingdom, significantly enhancing national pharmaceutical security.
Dr. Yasser AlObaida, Chief Executive Officer of Sudair Pharma Company, said: "At Sudir Pharma, we are pleased to collaborate with NUPCO and Sanofi in the establishment of this integrated facility. It will manufacture three types of insulin, including the latest biological insulin, which is widely used in diabetes treatment. The facility relies on the latest technologies throughout its manufacturing and packaging stages. The success of this initiative is driven by the unwavering support offered by all relevant authorities, including the Ministry of Health, the Ministry of Industry, and others, as well as the favorable policies and regulations in Saudi Arabia.'
Beyond production, the facility is designed to support the Kingdom's ambition to develop a sustainable healthcare ecosystem by equipping local talent with specialized skills. This focus aligns with the broader objectives of the Health Sector Transformation Program, a key pillar of Vision 2030 aimed at improving healthcare accessibility and advancing medical innovation.
Sanofi, a global healthcare leader, has been present in Saudi Arabia for more than 50 years and has continuously invested in initiatives that support the country's healthcare goals. The localization of insulin production reflects the company's deep-rooted partnership with the Kingdom and its dedication to strongly contribute to Saudi Vision 2030.
'As our CEO Paul Hudson said during his participation in FII8 last year, 'The sky is the limit for future collaborations in the Kingdom for Sanofi,'' Futnani remarked. 'While today is a milestone, it is just the beginning. We are committed to working alongside Saudi Arabia in shaping the future of healthcare and leaving a lasting impact for generations to come.'
The inauguration of the facility marks a pivotal step in Saudi Arabia's healthcare transformation, ensuring that patients have access to world-class treatment produced in Saudi, for Saudi, by Saudi.
© Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
4 days ago
- Zawya
Aspen boosts regional expansion via HQ in Riyadh
Riyadh – Aspen Pharmacare Holdings Limited, a global speciality and branded multinational pharmaceutical company, launches a new regional headquarters (HQ) in Riyadh, according to a press release. The Saudi expansion followed a series of Middle East investments in key therapeutic areas to meet the market demands and support Aspen's growth strategy, which focuses on talent development, localization, and partnerships. Daniel Vella Friggieri, Regional CEO Europe and Middle East, Aspen Pharmacare, said: 'The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity. Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030.' Wesam Nehad, Aspen Pharma RHQ General Manager, commented: 'Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East – namely, an efficient distribution network, operational excellence, and a highly skilled team.' It is worth indicating that Aspen focuses on marketing and manufacturing a wide range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments. It wide variety of product types includes steriles, oral solid dose, liquids, semi-solids, biologicals, and active pharmaceutical ingredients.
Zawya
6 days ago
- Zawya
Aspen reinforces Saudi market leadership with new Middle East region HQ in Riyadh
Riyadh, KSA – Aspen Pharmacare Holdings Limited ('Aspen'), a global specialty and branded multinational pharmaceutical company, has announced the establishment of a new regional headquarters in Riyadh, the capital of the Kingdom of Saudi Arabia (KSA). Following a series of Middle East investments in key therapeutic areas aligned with both patient needs and market demands, the new regional headquarters will support Aspen's regional growth strategy which includes a focus on three key pillars, namely, talent development, localization, and partnerships. Daniel Vella Friggieri – Regional CEO Europe & Middle East, Aspen Pharmacare, said: 'We are delighted to be strengthening our local presence in this crucial market. The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity. Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030.' KSA has experienced a dynamic transformation with a large influx of expatriate professionals. This country now ranks among Aspen's top five markets in the Middle East and Europe, underpinning the Group's strategy to significantly enhance its presence in this area. Aspen has also identified several Saudi-based initiatives as high-priority projects, further reinforcing the company's commitment to the Kingdom. Wesam Nehad, Aspen Pharma RHQ General Manager, added: 'Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East – namely, an efficient distribution network, operational excellence, and a highly skilled team. As we continue to grow, we are committed to expanding our reach and enhancing patient access to high quality, affordable medicine across the Kingdom and wider region'. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments, including manufacturing and commercial pharmaceuticals comprising injectable products, prescription and OTC medicines. Aspen's wide variety of product types includes steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. About Aspen Group Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. We have more than 9,300 employees at 63 established offices in over some 46 countries and territories and we improve the health of patients in more than 115 countries through our high quality, affordable medicines. For more information, visit
Web Release
6 days ago
- Web Release
ASPEN REINFORCES SAUDI MARKET LEADERSHIP WITH NEW MIDDLE EAST REGION HQ IN RIYADH
Aspen Pharmacare Holdings Limited ('Aspen'), a global specialty and branded multinational pharmaceutical company, has announced the establishment of a new regional headquarters in Riyadh, the capital of the Kingdom of Saudi Arabia (KSA). Following a series of Middle East investments in key therapeutic areas aligned with both patient needs and market demands, the new regional headquarters will support Aspen's regional growth strategy which includes a focus on three key pillars, namely, talent development, localization, and partnerships. Daniel Vella Friggieri – Regional CEO Europe & Middle East, Aspen Pharmacare, said: 'We are delighted to be strengthening our local presence in this crucial market. The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity. Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030.' KSA has experienced a dynamic transformation with a large influx of expatriate professionals. This country now ranks among Aspen's top five markets in the Middle East and Europe, underpinning the Group's strategy to significantly enhance its presence in this area. Aspen has also identified several Saudi-based initiatives as high-priority projects, further reinforcing the company's commitment to the Kingdom. Wesam Nehad, Aspen Pharma RHQ General Manager, added: 'Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East – namely, an efficient distribution network, operational excellence, and a highly skilled team. As we continue to grow, we are committed to expanding our reach and enhancing patient access to high quality, affordable medicine across the Kingdom and wider region'. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments, including manufacturing and commercial pharmaceuticals comprising injectable products, prescription and OTC medicines. Aspen's wide variety of product types includes steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients.
